J&J says its lung cancer drug combination keeps people alive longer
Johnson & Johnson said its lung cancer regimen – Rybrevant plus Lazcluze – keeps people alive for at least a year longer than AstraZeneca’s Tagrisso.
Johnson & Johnson said its lung cancer regimen – Rybrevant plus Lazcluze – keeps people alive for at least a year longer than AstraZeneca’s Tagrisso.